Profile: Hemispherx Biopharma, Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.

Ampligen

The Company’s double-stranded Ribonucleic Acid (RNA) drug product, Ampligen is in human clinical development for various therapeutically oriented studies, including treatment for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), HIV, renal cell carcinoma and malignant melanoma.

Alferon N Injection

The Company’s Alferon N Injection(R) product contains a multi-species form of alpha interferon. Alpha interferons are manufactured in three ways: by genetic engineering, by cell culture, and from human white blood cells. Alferon N Injection(R) [Interferon alfa-n3] (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon(R) Low Dose Oral (LDO)

The Company’s Alferon LDO is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon. It is an experimental immunotherapeutic stimulating an immune cascade response in the cells of the mouth and throat, enabling it to support systemic immune response through the entire body by absorption through the oral mucosa. The Company has conducted clinical trials of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) for Avian Flu and other lethal viral diseases, which have high acute death rates.

Oragens

The Company acquired licenses for Oragens, a set of oral spectrum antivirals and immunological enhancers. The 2', 5' oligoadenylate synthetase/RNase L system is a distributed pathway for the inhibition of viral replication and tumor growth. The bioactive 2-5A molecules are degraded by various hydrolytic enzymes. Analogues of these bioactive 2-5As, termed Oragen RNA compounds, have been produced to increase stability and maintain or increase biological activity without demonstrable toxicity.

The Company competes with Gilead Pharmaceutical, Pfizer, Bristol-Myers, Abbott Labs, GlaxoSmithKline, Merck and Schering-Plough Corp.